当前位置：   首页 > 需求大厅

 >  生产研发 

 >  药理毒理 

抑制细胞外神经信号的作用可以通过抑制受体或去除配位体来产生。我们需要一个实例或证据来证明抑制受体和损耗配体是怎么阻断信号的，比如可以变构小分子或大分子或竞争性抑制。具体看下面链接： https://www.innocentive.com/ar/challenge/9933720 AWARD: $20,000 USD | DEADLINE: 2/25/15 | ACTIVE SOLVERS: 19 | POSTED: 1/26/15 Inhibition of extracellular signaling can occur through an inhibition of a receptor or removal of a ligand. What evidence is there that one method of inhibition is more efficient or efficacious than the other at blocking signaling? The Seeker is specifically looking for well-supported examples of receptor/ligand inhibition where both methods of inhibition exist. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933720 Challenge Overview Inhibition of extracellular neuronal signaling can occur through the inhibition of a receptor or removal of a ligand. What evidence is there (or lack of) that one method of inhibition (inhibition of the receptor versus depletion of the ligand) is more efficient or efficacious than the other at blocking signaling? Inhibition can be allosteric or competitive, small molecule or large molecule. The Seeker is specifically looking for well-supported examples of receptor/ligand inhibition where both methods of inhibition exist. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on February 25, 2015. Late submissions will not be considered.   [更多]

药物代谢酶的过程中，肝脏是主要负责将药物基质脂溶性化合物转化为水溶性代谢物，可以很容易地通过肾脏排泄的。偶尔，这些代谢产物也会不恰当地和血蛋白结合，从而导致药物的不良反应。阿斯利康希望寻找一种定量测定共价结合细胞蛋白质的新方法。具体的链接请看下面： https://www.innocentive.com/ar/challenge/9933662 AWARD: $25,000 USD | DEADLINE: 3/16/15 | ACTIVE SOLVERS: 74 | POSTED: 1/16/15 Drug metabolism is the enzymatic process by which the body modifies pharmaceutical substrates. The liver is primarily responsible for reactions which convert lipid-soluble compounds into water-soluble metabolites that can easily be excreted by the kidney. Occasionally, these metabolites exhibit chemically reactivity towards host proteins, leading to inappropriate binding that may result in adverse drug reactions. AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding to cellular proteins. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933662 Challenge Overview When new medicines are introduced to the market, not only does the drug need to have a proven therapeutic benefit, but it also must possess an acceptable safety profile. To this end, drug development focuses on minimizing adverse drug reactions (ADRs) and idiosyncratic drug toxicities. ADRs are a major complication of drug therapy and come as a result of drug accumulation and/or the formation of chemically reactive metabolites (CRMs). Formation of CRMs within a cell poses an undesirable chemical liability and for this reason, AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding of metabolites to cellular proteins. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an   [更多]

重性抑郁障碍（MDD）是一种使人衰弱的精神障碍，在美国约有20000000流行病例。然而不同的抗抑郁药可用于治疗不同的抑郁症，，约50%的抑郁症患者的初始治疗结果不理想。最近有证据表明，在发病的几个小时内氯胺酮给药治疗难治性抑郁症已经显著有所改善。勃林格殷格翰公司寻找氯胺酮在人体中反应和持续的抗抑郁作用的机理。 Boehringer Ingelheim Challenge: Understanding the Antidepressant Effect of Ketamine TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $21,000 USD | DEADLINE: 1/15/15 | ACTIVE SOLVERS: 20 | POSTED: 12/15/14 1. The Challenge and qualification for the award Major depressive disorder (MDD) is a debilitating psychiatric disorder with about 20 million prevalent cases in the United States. Various antidepressants are available for treatment of patients suffering from MDD, however, about 50% of MDD patients do not respond adequately to initial treatments. Recent evidence shows that ketamine administered to patients with treatment resistant depression has resulted in marked improvement within hours of treatment. Boehringer Ingelheim (the Seeker) desires a working hypothesis for ketamine’s mechanism of action and sustained antidepressant effect. The submitted solutions will be considered for the award. There will be a guaranteed award for at least one submitted solution. The total payout will be $21,000, with at least one award being no smaller than $12,000 and no award being smaller than $3,000. 2. Additional application for Research Funding In addition to consideration for the award for the submitted Solutions, Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the Solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of this Challenge, and will require the submission of additional information. The decision to fund research will be at the discretion of the Seeker.   [更多]

截止日期：2015年1月6日 已有提案：8件 发布时间：14年11月20日 已选0个，还需要1个。 具体要求：双特异性抗体（BsAbs）在效力上优于常规的单克隆抗体（mAb），因为它们一定拥有两个特定的药理潜在优势。这可能导致比由或单一的单克隆抗体或甚至单抗联合治疗能够取得更大的效力。葛兰素史克对这一新兴的生物制药领域有着浓厚的兴趣，并取得了许多实验进展，比如从BsAb分子到临床实验研究。对于某些BsAb配对，我们也看到，双特异性抗体和单克隆抗体结合方法上的标准有所不同。 虽然对BsAb使用公认的最好的医疗应用是在控制T细胞活化方面，葛兰素史克公司对直接控制抗体方面也有兴趣，比如方便配体/受体靶对的抑制或激活的研究。 这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2015年1月6日下午11时59分（美国东部时间）收到，逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时，必须将其独有的知识产权（IP）的权利转让给举办方。 2.这个悬赏任务是必须寻找一种双特异性抗体识别机制来预测任何给定目标抗体的配对及协同作用能力。葛兰素史克因此热情邀请更广泛的研发人员，创建出这种方法，让双特异性抗体比等效单抗的联合治疗更有效。 3、投稿在此网站：https://www.innocentive.com/ar/challenge/9933655   [更多]

单人中标 赏金分配： $ 15000 截止日期：2014年12月4日 已有提案：75件 发布时间：2014年11月4日 已选0个，还需要1个。 具体要求： 研究人员想要一种小分子拮抗剂NK 3（神经激肽受体3，也被称为速激肽受体3）新的临床适应症。许多中枢神经系统的临床适应症NK3拮抗剂已经被考虑，如精神分裂症的治疗和药物成瘾的治疗。研究人员对NK3拮抗剂可以忍受的适应症，或其已知的药理作用特别感兴趣。最近的研究表明，有一种随着NK-3拮抗剂作用而降低的性激素的适应症。这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2014年12月4日下午11时59分（美国东部时间）收到，逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时，必须将其独有的知识产权（IP）的权利转让给举办方。 2.这个悬赏任务是必须寻找一种小分子拮抗剂NK 3（神经激肽受体3，也被称为速激肽受体3）新的临床适应症 3、在这个网站上投稿：New Disease Indications for NK3 (Tachykinin Receptor 3) Antagonists | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933526   [更多]

单人中标 赏金分配： $ 50,000 截止日期：计2015年1月12日 已有提案：57 件 发布时间：2014年11月6日 已选0个，还需要1个。 具体要求： 与年龄相关的黄斑变性（AMD）是造成50岁以上人的视力丧失的主要原因。黄斑变性会造成视网膜的中央点损害，并模糊，最后会使一个或两个眼睛发展到失明。虽然AMD已有少量模型存在，但并没有充分阐明疾病的病理，而且也不适合于彻底深入地筛选和开发药物。年龄相关性黄斑变性（AMD）被认为是由遗传和环境因素来触发一种复杂而且异质性疾病。正如它的名字所示的，随着年龄的增长AMD发病率增加，据估计，在美国，大约有800万55周岁以上的人具有中期或后期的疾病。 AMD出现的第一症状为黄斑色素的改变和被称为玻璃疣的视网膜下沉积物。疾病进一步发展可能导致视网膜色素上皮（RPE）细胞和光感受器细胞或新血管的血管渗透，出血和疤痕。光感受器细胞和视网膜色素上皮细胞之间的相互作用对于正常的视力功能是必不可少的。这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2015年1月12日下午11时59分（美国东部时间）收到，逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时，必须将其独有的知识产权（IP）的权利转让给举办方。 2.这个悬赏任务是必须寻找一种新的，临床前模型，描述光感受器细胞和视网膜色素上皮细胞之间的相互作用，在长期生理分化中对视力的影响，以方便对最近出现的新兴疗法进行疗效评价。 3、在这个网站投稿：Preclinical Models of Age-Related Macular Degeneration | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933641   [更多]